Cargando…

1α,25-dihydroxyvitamin D(3) mitigates cancer cell mediated mitochondrial dysfunction in human skeletal muscle cells

Cancer cachexia is associated with muscle weakness and atrophy. We investigated whether 1α,25-dihydroxyvitamin D(3) (1α,25(OH)(2)D(3)), which has previously been shown to increase skeletal myoblast oxygen consumption rate, could reverse the deleterious effects of tumor cell conditioned medium on myo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Zachary C., Craig, Theodore A., Wang, Xuewei, Delmotte, Philippe, Salisbury, Jeffrey L., Lanza, Ian R., Sieck, Gary C., Kumar, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812288/
https://www.ncbi.nlm.nih.gov/pubmed/29366785
http://dx.doi.org/10.1016/j.bbrc.2018.01.092
Descripción
Sumario:Cancer cachexia is associated with muscle weakness and atrophy. We investigated whether 1α,25-dihydroxyvitamin D(3) (1α,25(OH)(2)D(3)), which has previously been shown to increase skeletal myoblast oxygen consumption rate, could reverse the deleterious effects of tumor cell conditioned medium on myoblast function. Conditioned medium from Lewis lung carcinoma (LLC1) cells inhibits oxygen consumption, increases mitochondrial fragmentation, inhibits pyruvate dehydrogenase activity, and enhances proteasomal activity in human skeletal muscle myoblasts. 1α,25(OH)(2)D(3) reverses the tumor cell-mediated changes in mitochondrial oxygen consumption and proteasomal activity, without changing pyruvate dehydrogenase activity. 1α,25(OH)(2)D(3) might be useful in treatment of weakness seen in association with CC.